Details of the Drug Formulations

General Information of Drug (ID: DM5J64S)

• Drug Name: Miglustat Drug Info
• Synonyms: BuDNJ; Butyldeoxynojirimycin; Miglustatum; NBV; Vevesca; Zavesca; Miglustat [USAN]; OGT 918; SC 48334; SC48334; Miglustat, Hydrochloride; N-Butyl deoxynojirimycin; N-Butyl dnj; N-Butyldeoxynojirimycin; N-Butylmoranoline; NB-DNJ; OGT-918; SC-48334; Zavesca (TN); Miglustat (USAN/INN); N-Bu-DNJ; N-Butyl-DNJ; N-Butyl-deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol

Indication

Disease Entry	ICD 11	Status	REF
Niemann-Pick disease type C		Approved	[1]
Type 1 gaucher disease	5C56.0Y	Approved	[2]
Gaucher disease	5C56.0Y	Investigative	[1]

• Therapeutic Class: Anti-HIV Agents
• Cross-matching ID:
  PubChem CID: 51634
  ChEBI ID: CHEBI:50381
  CAS Number: 72599-27-0
  TTD ID: D0HR8Z
  ACDINA ID: D00434

Full List of Drug Formulations Containing This Drug

Miglustat 100 mg capsule

Company	Formulation ID	FDA Description
CoTherix	F14063	Magnesium stearate; Ferrosoferric oxide; Titanium dioxide; Povidone k30; Gelatin, unspecified; Shellac; Sodium starch glycolate type a potato

References

• [1] Miglustat FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4841).